SILCAAT
SILCAAT
Subcutaneous, Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy. An international, multicentre, Phase-3 clinical trial that examined whether IL2 plus combination antiretroviral therapy in adults with advanced HIV infection would reduce the risk of AIDS-associated opportunistic diseases or death more effectively than combination antiretroviral therapy alone.Conclusion
While the CD4+ T-cell counts (a surrogate marker of participants who received IL2) rose an average of 59 cells/mm3 higher than those of participants in the control group—a statistically significant difference—the elevation did not offer any health advantage to HIV-infected individuals.